Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
Blood
|
July 5, 2005
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
Bronno van der Holt, Bob Löwenberg, Alan K Burnett, et al.
Blood
|
August 15, 2002
A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL)
Urban Novak, Elisabeth Oppliger Leibundgut, Jörg Hager, et al.
Blood
|
February 21, 2004
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio B Cogliatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2005
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI
Günther Gruber, Marco Bonetti, M Laura Nasi, et al.
Ejhaem
|
October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
Stefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
Per Karlsson, Bernard F Cole, Karen N Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
Marco Colleoni, David Zahrieh, Richard D Gelber, et al.
Lancet (London, England)
|
May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews
|
July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
ESMO Open
|
November 16, 2016
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Christian Dittrich, Michael Kosty, Svetlana Jezdic, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
Blood
|
July 5, 2005
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
Bronno van der Holt, Bob Löwenberg, Alan K Burnett, et al.
Blood
|
August 15, 2002
A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL)
Urban Novak, Elisabeth Oppliger Leibundgut, Jörg Hager, et al.
Blood
|
February 21, 2004
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Michele Ghielmini, Shu-Fang Hsu Schmitz, Sergio B Cogliatti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2005
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI
Günther Gruber, Marco Bonetti, M Laura Nasi, et al.
Ejhaem
|
October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
Stefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
Per Karlsson, Bernard F Cole, Karen N Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2005
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
Marco Colleoni, David Zahrieh, Richard D Gelber, et al.
Lancet (London, England)
|
May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews
|
July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data
Julia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
ESMO Open
|
November 16, 2016
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Christian Dittrich, Michael Kosty, Svetlana Jezdic, et al.
Page
of 7